University of Patras
Μελέτη της μοριακής στόχευσης κυττάρων του πλειόμορφου γλοιοβλαστώματος με αναστολείς της αγγειογένεσης και μορίων του μονοπατιού her
Abstract
dc:descriptionGlioblastoma is considered to be one of the most fatal among the malignancies in human with median survival between 12-15 months. The conventional chemotherapy cannot change the fate of these patients. Recent advances in molecular biology have shed light in the various mechanisms recruited by malignant cells in order to proliferate, metastasize and escape apoptosis. Studies in glioblastoma have already shown up-regulation in the function of tyrosine kinase receptors such as EGFR, PDGFR and VEGFR. Besides this, in the more recent years, research supports the significant role of integrins in the migration process of glioblastoma cells. In the new era of tyrosine kinase inhibitors (TKIs), where their main mechanism of action is by blocking various growth factor receptors, it has to be determined a possible contribution in the fight against glioblastoma. Initially, it was estimated a possible effect of sunitinib and lapatinib applied either alone or in combination, on U87 and M059K glioma cells’ proliferation and apoptosis using doses of 0,01 μM, 0,1 μM, 1μM and 10 μM. The proliferation was estimated using the 3-[4,5-dimethylthiazol-2-yl]-2,5 dimethyltetrazolium bromide assay and apoptosis using annexin V/propidium iodide detection assay. Migration assay was performed using Boyden chamber assay. The release of MMP-2 and MMP-9 into the culture medium of U87 and M059K cells was measured by zymography. Furthermore, a possible implication of the tested agents in the formation of EGFR-integrin β1 complex, VEGFR-integrin β3 and PDGFR-integrin β3 complexes formation was studied. Immunoprecipitation and western blot analysis were used for studying the complex formation of EGFR, PDGFR and VEGFR with integrins. Validation of the results was made using immunofluorescence assay. Also, similar experiments were performed for the effect of sunitinib and lapatinib in FAK phosphorylation.The results showed that both tested agents decreased cell proliferation in a dose-dependent manner 48 h after their application in both cell lines either alone or in combination. The results in cell proliferation were in line with the increase in apoptotic cells after their treatment with the tested agents. Furthermore, the ability of U87 and M059K cells to migrate was inhibited either by each agent alone or in combination. Both agents did not affect MMP-2 and MMP-9 levels in U87 cells, however, MMPs levels were decreased in M059K cells, 48h after their treatment with sunitinib either alone or in combination with lapatinib. Additionally, a time course study for the effect of lapatinib on EGFR-integrin β1 complex revealed an inhibition in complex formation up to 30 min after agent application. Likewise, sunitinib inhibited complex formation of VEGFR-integrin β3 complex within 2h after its application without affecting PDGFR-integrin β3 complex. The previously-described interruption of complexes formation was confirmed with an immunofluorescence assay.
Degree
thesis:*- Grantor dc:publisher
- University of Patras
- Year dc:date
- 2013
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Dimitropoulos, Konstantinos
- Δημητρόπουλος, Κωνσταντίνος
Subjects
dc:subject × 24- Γλοιοβλαστώματα
- Αναστολείς υποδοχέων κινάσης τυροσίνης
- Ιντεγκρίνες
- Μεταστάσεις
- Πολλαπλασιασμός
- Απόπτωση
- Υποδοχείς αυξητικών παραγόντων
- Καρκίνος
- Σημεία εστιακής προσκόλλησης
- Glioblastomas
- Tyrosine kinase inhibitors
- Cancer
- Integrins
- Metastasis
- Proliferation
- Apoptosis
- Growth factor receptors
- FAK
- Ιατρική και Επιστήμες Υγείας
- Βασική Ιατρική
- Κλινική Ιατρική
- Medical and Health Sciences
- Basic Medicine
- Clinical Medicine
Rights
dc:rights- Statement dc:rights
-
- BY_NC_ND
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/35548